While Somatuline lost pace in Q3 – due to lower patient diagnoses amidst the pandemic – Cabometyx witnessed an acceleration on the back of a solid performance in Western Europe. Onivyde was back in the black led by volume growth in the US. Ipsen continued to realize cost savings and thus the FY20 targets were reiterated. Given that the pipeline has achieved notable progress recently, the mid-term growth prospects appear robust. The new CEO will unveil his strategy at the upcoming CMD.
23 Oct 2020
Despite marginal sales miss in Q3, FY20 targets reiterated; pipeline progressing well
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Despite marginal sales miss in Q3, FY20 targets reiterated; pipeline progressing well
While Somatuline lost pace in Q3 – due to lower patient diagnoses amidst the pandemic – Cabometyx witnessed an acceleration on the back of a solid performance in Western Europe. Onivyde was back in the black led by volume growth in the US. Ipsen continued to realize cost savings and thus the FY20 targets were reiterated. Given that the pipeline has achieved notable progress recently, the mid-term growth prospects appear robust. The new CEO will unveil his strategy at the upcoming CMD.